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Today, tamoxifen is one of the world’s best-selling hormonal breast cancer drugs.
However, it was not always so. Compound ICI 46,474 (as it was first known) was
synthesized in 1962 within a project to develop a contraceptive pill in the pharmaceutical
laboratories of ICI (now part of AstraZeneca). Although designed to act as an
anti-estrogen, the compound stimulated, rather than suppressed ovulation in women.
This, and the fact that it could not be patented in the USA, its largest potential market,
meant that ICI nearly stopped the project. It was saved partly because the team’s
leader, Arthur Walpole, threatened to resign, and pressed on with another project: to
develop tamoxifen as a treatment for breast cancer. Even then, its market appeared
small, because at first it was mainly used as a palliative treatment for advanced breast
cancer. An important turning point in tamoxifen’s journey from orphan drug to best-
selling medicine occurred in the 1980s, when clinical trials showed that it was also useful
as an adjuvant to surgery and chemotherapy in the early stages of the disease. Later,
trials demonstrated that it could prevent its occurrence or re-occurrence in women at
high risk of breast cancer. Thus, it became the first preventive for any cancer, helping
to establish the broader principles of chemoprevention, and extending the market for
tamoxifen and similar drugs further still. Using tamoxifen as a case study, this paper
discusses the limits of the rational approach to drug design, the role of human actors, and
the series of feedback loops between bench and bedside that underpins pharmaceutical
innovation. The paper also highlights the complex evaluation and management of risk
that are involved in all therapies, but more especially perhaps in life-threatening and
emotion-laden diseases like cancer.
Keywords: synthetic anti-estrogen, contraceptive pill, breast cancer, chemoprevention, risk evaluation and
management, adjuvant therapy
INTRODUCTION
Today, tamoxifen (brand name Nolvadex) is one of the world’s best-selling hormonal breast cancer
drugs. However, it was not always so. Compound ICI 46,474 (as it was first known) was synthesized
in 1962, quite unusually for the time, by a female chemist: Dora Richardson, who was responsible
for making triphenylethylene derivatives within a project to develop a contraceptive pill in the
pharmaceutical laboratories of the British chemical group ICI (now part of AstraZeneca). Although
designed to act as an anti-estrogen, the compound was found to stimulate, rather than suppress
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ovulation in women. This, and the fact that at first it could not
be patented in the USA, its largest potential market, meant that
ICI nearly stopped the project. If it was saved, it was partly
because the team’s leader, Arthur Walpole, threatened to resign,
and pressed on with another project: to develop tamoxifen as
a treatment for breast cancer. Even then, its market appeared
small, because at first it was mainly used as a palliative treatment
for advanced breast cancer. An important turning point in
tamoxifen’s journey from orphan drug to best-selling medicine
occurred in the 1980s, when the results of clinical trials showed
that it was also useful as an adjuvant to other forms of therapy
in the early stages of the disease. Later, trials demonstrated
that it could prevent its occurrence or re-occurrence in women
at high risk of developing breast cancer. Thus, it became the
first chemopreventative for any cancer, helping to establish
the broader principles of chemoprevention, and extending the
market for tamoxifen and similar drugs further still.
Hailed as a pioneering medicine that has saved the lives of
thousands of women1, much has been written about tamoxifen,
especially in recent years by Craig Jordan, the researcher who
was influential in the latter part of its history (Maximov et al.,
2016). However, as the public’s and the medical profession’s
dependence on drugs not only to treat, but also to prevent an
ever growing variety of conditions has come under increasing
scrutiny (Greene, 2007), tamoxifen has also been investigated
by sociologists as an example of what they describe as the
“biomedicalization” of society, i.e., the shift in the use and
meaning of drugs from treatment to prevention, involving a cost-
benefit calculation that is seldom openly discussed (Fosket, 2010,
pp. 341–348; Löwy, 2010, pp. 185–188; Löwy, 2012).
There is another strand in the literature, which is somewhat
less well-developed, and concerns tamoxifen at once as an
emblematic and an idiosyncratic example of pharmaceutical
innovation. For the history of tamoxifen suggests a model of
pharmaceutical innovation that is far more complex than a linear
model from bench to bedside (Schwartzman, 1976; Howells and
Neary, 1988; Gambardella, 1995; Landau et al., 1999). Rather,
it incorporates numerous dead ends, feedback loops, as well as
serendipitous observations made by individual researchers (and
associated with other discoveries, in this instance the isolation
of the estrogen receptor). Hence, the scientists whose work has
shaped pharmaceutical innovation are an important part of the
story—in the case of tamoxifen, not only Richardson, but also
Walpole, the biologist who led the research team at ICI and
provided the link between the different projects within which
tamoxifen was developed (Jordan, 1988), and, for the later stage
in the drug’s tortuous journey, Jordan.
At a time when the drying up of old drug pipelines has
led to anxieties about the end of the Therapeutic Revolution
and the need to find new models of drug discovery to replace
those which produced many of the blockbuster drugs we know
today, tamoxifen therefore presents an opportunity to explore
the historically contingent nature of pharmaceutical innovation,
addressing several of the questions posed by the editors (see
1In 2003 it was estimated that 400,000 women were alive thanks to the drug, and
millions have benefited from extended disease-free survival (See Jordan, 2003).
their introduction to this special issue). Using the research
and development reports of the company that developed the
drug (ICI)2, an unpublished history of tamoxifen, written by
Richardson and accompanied by letters from patients3, as well
as some of the numerous publications on the topic, the paper
will show how the early history of the drug shaped its fate in
the medical marketplace, and therefore deserves to be better
understood than it is at present. The paper argues that its origins
as a contraceptive pill rather than a cancer remedy meant that
concerns over side-effects, alongside its ability to counteract
the action of estrogen, dominated the company’s research and
development agenda. Hence patients’ voices, which provided
indications the drug’s safety and efficacy at once directly and
indirectly, helped to define this agenda, and the absence of side-
effects relative to its anti-estrogenic activity would become one
of the key selling points of tamoxifen as an anti-cancer drug
compared to alternative treatments.
However, because of its very ability to prolong life in women
suffering from breast cancer, tamoxifen was later found to
have a number of potentially serious long-term side-effects,
which range from pulmonary thrombosis to endometrial cancer.
Nevertheless, its usefulness in treating and preventing a major
cause of death in women hasmeant that, to this day, it remains on
the WHO’s List of Essential Medicines (WHO, 2015). This paper
will therefore also highlight the complex evaluation of risk that is
involved in all therapies, but more especially perhaps in diseases
as threatening and emotionally charged as cancer, not only at the
regulatory and clinical levels, but also at the individual level of the
patient.
RESULTS
Before focusing on the development of tamoxifen, it is useful to
describe the background for the different projects that led first to
its synthesis, second to its early trajectory as an anticancer drug,
for it illustrates not only the non-linear nature of pharmaceutical
innovation, but also the lengthy accumulation of in-house
scientific knowledge and technical know-howwhich underpins it,
and yet is rarely brought to the fore in histories of drug discovery
(Weatherall, 1990; Sneader, 2005; Ravina, 2011).
The Use of Sex Hormones and Synthetic
Analogues in Cancer
The link between hormones and cancer has been known at least
since 1916 (Lathrob and Loeb, 1916). However, their usage in
the treatment of cancer depended on their isolation, purification
and chemical determination, which was not achieved until the
1930s in the case of sex hormones. One such hormone was the
follicular hormone (Follicle-Stimulating Hormone, FSH), which
was prepared by the Roussel Laboratories, a French company
2AstraZeneca, formerly ICI (hereafter AZ), research and other reports: Oral
Contraception (AZ CPR 70: 1960-64); Endocrinology and Fertility (AZ CPR
101: 1965-72); Viruses and Cancer (AZ CPR 54-55: 1958-64). These unpublished
reports were made accessible to me between 2002 and 2009 by kind permission
from AstraZeneca.
3D. N. Richardson, “The history of Nolvadex” (AZ PH27039 B, 13 May 1980).
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specializing in biologicals, and supplied to Antoine Lacassagne at
the Institut du Radium in Paris. Using this hormone, Lacassagne
was able to show a direct link between estrogens and the
appearance of breast cancer in mice (Lacassagne, 1932, 1936).
But natural estrogens were difficult to obtain in the quantities
required for large-scale experiments. A major turning point
occurred when E.C. (later Sir Charles) Dodds, working at the
Middlesex Hospital in London in collaboration with researchers
at the Dyson Perrins Laboratory in Oxford, discovered that
the synthetic compound stilboestrol had estrogenic properties
(Dodds et al., 1938). Dorothy Crowfoot (later known by
her married name, Hodgkin), who worked nearby at Oxford
University’s Inorganic Chemistry Department, established using
X-ray crysallography that its chemical structure resembled
estrogen (Carlisle and Crowfoot, 1941). Inexpensive to make and
apparently well tolerated in patients, stilboestrol was therefore
widely prescribed for cases of estrogen deficiency, especially in
menopausal women (Sneader, 2005, p. 197). Although it would
later be linked to cases of vaginal or cervical adenosarcomas in
daughters of women who had been prescribed the drug in their
first trimester of pregnancy (to avoid unwanted abortion; see
Gaudillière, 2014), it was also the first synthetic drug to be used
for treating cancer (Weatherall, 1990, pp. 217–218). Indeed, in
1939, Charles Huggins of the University of Chicago successfully
treated cases of prostate cancer with stilboestrol (known as
diethylstilbestrol in the US; Huggins and Hodges, 1941), and by
1950 a co-operative trial had shown that the synthetic estrogen
was effective in delaying the progress of this type of malignant
disease (Nesbitt and Baum, 1950). However, breast cancer proved
more difficult to treat, as it could either be inhibited or stimulated
by administration of estrogen.
Following the publication of Dodds’ findings, synthetic
substances with a similar structure were examined for estrogenic
activity, such as, triphenylethylene. These substances, which
could not only be mass produced, but also be chemically
modified to obtain derivatives with anti-estrogenic activity,
therefore became compounds of choice for studies in Britain and
elsewhere. One of the organizations that studied it was ICI, which
I turn to now.
ICI and Cancer Research
The company’s interest in cancer was a long-standing one. When
triphenylethylene was found by Charles Scott, a researcher in
Edinburgh, not only to be active bymouth, like stilboestrol, but to
have a durable estrogenic action, and therefore to have potential
as an alternative to stilboestrol, Arthur Walpole, a biologist who
had joined ICI’s Medicinal Section in 1938, began carrying out
some exploratory work with the substance. This work led to
the synthesis of various triphenylethylene derivatives, including
triphenylmethylethylene (M 612) and triphenylchloroethylene
(registered in 1940 under the name Gynosone)4. In 1942,
these compounds were supplied by the company for trials
in breast cancer to Alexander Haddow of the Chester Beatty
Institute in London, Edith Patterson at the Christie Hospital
in Manchester and their collaborators. Although improvements
were only temporary, there was clear evidence that Gynosone in
4Richardson, “The history of Nolvadex.”
particular caused regression and therefore could be beneficial in
the treatment of breast cancer (Haddow et al., 1944; Walpole and
Paterson, 1949).
Meanwhile, on the other side of the Atlantic, the compounds
known as “nitrogen mustards,” which were being studied as
part of a chemical warfare research programme, were shown to
inhibit the growth of blood and lymph tumors by Goodman
and Gilman at the University of Yale, a discovery often hailed
as the beginning of cancer chemotherapy5. Despite this wartime
work being top-secret, Walpole and Haddow were also able
to investigate these compounds, thanks to an Anglo-American
agreement to exchange scientific information (Weatherall, 1990,
p. 218). Another, parallel study relating to cancer at ICI
involved anti-metabolites. Following the discovery that ICI’s
novel anti-malarial drug Paludrine was converted in the body
to cycloguanine, an active metabolite which interferes with
purine biosynthesis, and spurred by the announcement that
BurroughsWellcome’s drug 6-MP was effective against leukemia,
the search for anti-metabolites began at ICI under the leadership
of Frank Rose, who had run their anti-malarial programme
during the war. Rose became ResearchManager of the Chemistry
Department in 1954, whilst remaining involved in bench work.
As well as the search for alkylating agents, synthetic estrogens,
and anti-metabolites, Rose also encouraged investigations into
carcinogenesis, which was a rare interest for researchers working
on cancer chemotherapy at that time (Suckling and Langley,
1990, pp. 507–508).
At first, ICI’s approach to cancer was therefore largely
empirical, involving the synthesis of derivatives of compounds
that had known anti-tumor properties, without a formal cancer
research programme. However, once plans had been made to
build a pharmaceutical research center at Alderley Park near
Manchester, and ICI started organizing its research in team
projects, Cancer became such a project in 1955. The project was
entitled “Cancer and Viruses: antibacterials6,” and its team leader
was the biologist E. Weston Hurst. Alderley Park opened in 1957,
and between 1957 and 1960 Cancer and Viruses separated into
two different projects.
During that time Cancer was merged with a new project
to find an oral contraceptive, led by Arthur Walpole. Then, in
1960, the discovery of the natural antiviral substance interferon,
and ICI’s involvement in its study in collaboration with the
Medical Research Council (see Pieters, 2005, Chapters 5–
6), led to Viruses and Cancer coming together again. Oral
Contraception therefore split away from Cancer, with Walpole
working in parallel on both projects. His involvement in the
Oral Contraception project (which in 1963 was re-named
“Endocrinology,” and later “Fertility,” reflecting a gradual change
in the research emphasis) would ensure that breast cancer
remained an important focus for both his teams. It was within
5There compounds were later understood to work by alkylation—i.e., the transfer
of an alkyl group from one molecule to another, in the case of anti-cancer agents
attaching it to DNA, thus inhibiting cancer cell division—hence such compounds
became known as “alkylating agents” because of their mechanism of action.
6Since the 1930s it was known that viruses can induce tumors in laboratory mice.
The oncogenic potential of a number of virus groups, including adenoviruses,
herpesviruses, and poxviruses, was identified in the 1950s and 1960s (See Rigby
and Wilkie, 1985).
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this Oral Contraception project that tamoxifen (Nolvadex), a
triphenylethylene derivative, was synthesized and subsequently
developed, initially as a contraceptive pill.
ICI, Oral Contraception, and the Origins of
Tamoxifen
The first contraceptive pill had been synthesized in the early
1950s, and in 1956 Walpole wrote a survey entitled “The
technical possibility of oral contraception7,” which—as had
become customary within ICI by that time (see Quirke, 2005)—
gave an overview of the field to enable ICI to decide whether or
not it was worth entering.
Walpole began by introducing the context in which such a
pill would be developed. In doing so, he showed the extent
to which contemporary concerns, which included anxiety over
population growth, a decrease in death rates, food shortages, and
an awareness of important differences between the developed
and developing world, were internalized and acted upon by
companies such as ICI. Then, in the main body of his report,
Walpole enumerated the requirements for contraception:
1. it should not “offend social or religious scruples” and as little
as possible the “aesthetic feelings” of those who might wish to
avail themselves of it (however, he added, such considerations
remained outside the scope of experimental biology);
2. it should be cheap enough to be readily available and simple
enough to use by any people “intelligent enough to realize the
possible consequence of coitus and to know whether or not
they wished to conceive”;
3. it should be effective over a known period of time with no
prejudice to subsequent fertility;
4. it should not depend on a local action contemporaneous with
coitus or any form of treatment which must be timed in a
complex or critical manner in relation to the menstrual cycle;
5. it should involve only occasional dosage by mouth.
After describing what at the time was understood about
the physiology of reproduction, he went on to list the
technical possibilities of contraception at different stages in the
reproductive cycle, from (a) spermatogenesis and sperm, to (b)
ovulation and ovum, (c) fertilization, (d) fertilized ovum, (e)
implantation of embryo, and lastly (f) development of embryo.
On the basis of substances already known to act as
contraceptives, he concluded that it “would seem possible to
produce temporary infertility in men by giving androgens, and of
thesemethylsterone is active bymouth.” He added that it was also
possible “either to prevent conception or interrupt pregnancy at
a very early stage in women by giving estrogens by mouth,” but
that such treatments must be free from undesirable side-effects.
Among the newer partly synthesized steroids now becoming
available, he believed that substances might be found that were
be more specifically antagonistic toward progesterone (anti-
progestins), and he argued that these would seem more suitable
7Walpole, “The technical possibility of oral contraception” (AZ ICP 10695, 13 June
1956).
for continued use8. Other substances from natural sources, such
as, the Lithospermum ruderale, a North American plant with a
small white flower that could also be found in English hedgerows
and was being investigated at the time by the Medical Research
Council (Marks, 2001, pp. 49–50), appeared to him as “rather
more suspect,” and he acknowledged that clinical evidence was
lacking, not only concerning these natural compounds, but also
human contraception more generally.
As to the other substances that might be considered for
contraception, toxicity was amajor problem, such as the anti-folic
drug aminopterin, for not only did it act as an early abortifacient,
but it carried serious toxic hazards, like some of the other anti-
metabolites. Similar concerns were associated with biological
alkylating agents, which were potentially mutagenic and
carcinogenic. Hence, taking into account both the requirements
for contraception and the need to avoid toxic effects, especially
since contraceptive substances were intended for use in normally
young and healthy adults (Oudshoorn, 2002, pp. 123–157), the
search for triphenylethylene derivatives, alongside investigations
of natural and part-synthesized steroids, became the preferred
course of action, as evidenced by ICI’s research reports9.
ICI were not alone in pursuing the triphenylethylene
route. Indeed, when Leonard Lerner, a researcher working
on a cardiovascular research program at the American drug
company Merrell, reported in 1958 that a newly synthesized
compound, MER 25 (ethamoxytriphetol), not only resembled
structurally triphenylethylene, but had anti-estrogenic activity
on both spayed and intact female rats, his discovery stimulated
laboratory research and clinical investigation of other potential
anti-fertility agents among triphenylethylene derivatives. ICI
considered acquiring the drug under license from Merrell in
order to study and potentially exploit it as a contraceptive,
but interest in it waned, for in the meantime ICI had found
that another compound, ICI 22,365 [N:N-bis (allylthiocarbamyl)
hydrazine], which they employed in analytical chemistry and
were currently investigating as an anti-parasitic for use in the
poultry industry, prevented the development of sex organs and
secondary characteristics such as the emergence of combs in
chicks10. This finding led Walpole’s team, which at that stage
included G. E. Paget and J. K. Walley working on the biological
side (while Dora Richardson and G. A. Snow worked on the
chemistry), to test the compound in male and female rats,
producing evidence that it caused a selective and reversible
inhibition of the gonadotrophic functions of the pituitary in rats,
and prevented pregnancy either by inhibiting ovulation, or by
preventing implantation (the precise mechanism of action was
yet unclear). In a report written in September 1960, Walpole
wrote that the compound not only provided an interesting lead
in oral contraception, but also in hormone-dependent cancers of
8G.D. Searle’s norethynodrel, brand name Enovid, had been patented in 1955, and
Syntex’s norethisterone, brand name Ortho-Novum, was patented in 1956. NB:
both were progesterone analogues containing some oestrogen (See Marks, 2001,
pp. 72–73).
9Walpole, “Steroids as oral contraceptives” (PD/B 353, 13 Nov. 1958); AZ CPR 70
“Oral Contraception.”
10Richardson, “The history of Nolvadex”—MER 25 was also later shown in clinical
trials to have low potency and unacceptable side effects.
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the prostate and breast, and it was decided that “if an alternative
patentable compound were found which, in laboratory tests,
proved superior (or even equivalent to it), then this compound
should replace 22,365 in clinical studies11.”
The most promising compound to come out of this
programme, ICI 33,828 (which had a similar structure to 22,365),
was therefore tested in pre-menopausal patients with mammary
carcinoma, which was justified on the grounds that it might
have a therapeutic as well as an anti-fertility effect. It was also
tried in prostatic cancer, however the clinicians involved in these
trials at the MRC Clinical Endocrinology Unit in Edinburgh
received complaints from patients about nausea, anorexia, and
occasional vomiting. Walpole also discovered that, before trials
with 33,828 could begin, 22,365 had been given in November
1960 to a psychotic patient who was 15 weeks pregnant in order
to induce abortion. However, the drug had failed to terminate the
pregnancy, and estrogen excretion had remained unaffected by
the treatment. The fetus, which had therefore had to be removed
surgically, appeared normal. At the same time as plans for more
extensive clinical studies, preferably closer to home so that his
team could be more directly involved in the trials, Walpole
therefore also made plans to develop more sensitive assay
methods for gonatrophins in urine, blood, and pituitary, to better
assess the clinical effects of their lead compound, and obtainmore
reliable measures of activity in animal experiments12. Shortly
afterwards, in 1962, Mike Harper, a young endocrinologist who
would play a significant part in the tamoxifen story, was invited
to join the team.
Meanwhile, at Merrell, researchers had pressed on with the
search for novel triphenylethylenes and in 1961 discovered
that MRL 41 (also known as clomiphene, or chloramiphene,
brand name Clomid), which was in fact an ether derivative of
Gynosone, also inhibited pituitary gonadotrophins although it
showed weak estrogenic activity. Remembering the earlier trials
with Gynosone and M 612, Walpole therefore suggested to his
team that they develop and examine an ether derivative of M
61213. The compounds they prepared in 1961 not only inhibited
implantation of the fertilized ovum in the rat at a low dose (below
that at which they would show estrogenic activity), but with the
addition of a methoxy group they also had a greater duration of
action. After the arrival of Harper, whose new series of biological
tests helped to produce a clearer picture of the structure–activity
relationships of triphenylethylenes, the programme of chemical
synthesis was therefore stepped up. The team had grown, and
as well as Walpole, Walley, and Richardson, it now included
several members of the Biology Group: A. M. Barrett, M. J. K.
Harper, G. E. Paget, Miss J. M. Peters, and J. M. Thorp, of the
Chemistry Group: R. Clarkson, E. R. H. Jones, J. K. Landquist, B.
W. Langley, W. S. Waring, and of the Biochemistry Group: W.
A. M. Duncan. It was hoped that, with such increased resources,
11A. L. Walpole and G.E. Paget, “Pituitary inhibitors” (AZ CPR 70/1B: Oral
Contraception Sep. 1960).
12Walpole et al. “Pituitary Inhibitors” (AZ CPR 70/2B: Endocrinology, June 1961).
NB: the reports were re-named “endocrinology” after the study of steroids and
their action on cholesterol metabolism was included in the project.
13Richardson, “The history of Nolvadex.”
ICI could improve upon both clomiphene and a new Upjohn
product with similar activity, U 11,555, by finding alternatives
with less estrogenic and pituitary-inhibitory activity relative to
their anti-fertility activity. For, by then, clinical studies of ICI
33,828 had produced disappointing results: not only did it have
unpleasant and worrying side effects (nausea, drowsiness, a fall
in thyroid function measured by thyroidal I132 uptake, and a rise
in serum cholesterol)14, but the inhibition of ovulation could not
be achieved without suppressing menstruation, which made it
undesirable as an oral contraceptive in women15.
Among the newly synthesized triphenylethylenes, Harper
drew up a short list for further study, primarily as potential
anti-fertility agents. These included the dimethylamino ethoxy
compound ICI 46,474 (later known as tamoxifen, brand name
Nolvadex). It had been synthesized in 1962 by Richardson,
and Harper selected it for additional tests and for preliminary
toxicity studies. At the same time, the company lodged patent
applications to protect ICI 46,474 and related compounds
from competitors16. As well as providing basic data on these
compounds, Patent GB1013907 covered a number of potential
therapeutic uses, including cancer. It read:
The alkene derivatives of the invention are useful for the
modification of the endocrine status in man and animals and they
may be useful for the control of hormone-dependent tumors or
for the management of the sexual cycle and aberrations thereof.
They will also have useful hypocholesteraemic activity17.
ICI 46,474 (1962–67)
Although marred by a number of dead ends, which were partly
due to ICI’s strategy of closely following their competitor’s
activities and using their compounds as leads in the search
for new, patentable products, the early phase of the Oral
Contraception programme shaped tamoxifen and determined
its future in many ways. The compounds developed within this
programme were designed to act as contraceptive pills, yet from
the beginning their usefulness in breast cancer was explored
in close parallel. This dual objective was pursued as a result
of Walpole’s own research interests, and thanks to the fruitful
collaborations he established both with endocrinologists andwith
clinicians working in cancer. The feedback loops between bench
and bedside which this relationship created, and which led to
a series of twists and turns that would become the hallmark of
the tamoxifen story, meant that the compounds functioned both
as research tools to study hormone function and metabolism
in the laboratory, and as experimental treatments in the clinic.
Importantly, the dual objective of developing a contraceptive pill
whilst assessing the usefulness of compounds in breast cancer
(even if as we have seen this was also a means of testing drugs
14Cholesterol levels had become a serious concern since Merrell’s new drug MER
29 (Triparanol) had been found to cause irreversible cataracts by interfering with
cholesterol biosynthesis, and had had to be withdrawn from the market. B. W.
Langley and A. L. Walpole (AZ CPR 70/5B: Endocrinology May 1963). See also
Richardson, “The history of Nolvadex.”
15B. W. Langley and A. L. Walpole (AZ CPR 70/5B: Endocrinology May 1963).
16The compounds were covered by patents GB 1013907 and 1064629.
17Quoted in Jordan (2006), p. 39.
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before administering them to healthy women), also meant a
constant preoccupation with side effects, and the low toxicity of
tamoxifen relative to its potency would turn out to be one of its
crucial advantages over its competitors.
A triphenylethylene derivative, with groups and side chains
to enhance its anti-estrogenic and pituitary-inhibitory effect
and prolong its duration of action, without interfering with
its anti-fertility activity, ICI 46,474 had been demonstrated as
the most potent and least toxic of all the compounds tested
by June 196418. But what exactly was it? In the process of
gathering data for patent applications, scaling up production
and preparing a submission to the newly formed Committee on
Safety of Medicines (CSD), uncertainty arose as to the precise
structure of the compound. Using an NMR spectrometer recently
acquired by the company, in 1964 G. R. Bedford, a spectroscopist
who had joined ICI’s Pharmaceutical Division in 1963, showed
that many of the active compounds synthesized so far were a
mixture of isomers. However, it was unclear in which isomer
the anti-estrogenic activity resided (did it reside in the cis, or
the trans isomer?). The isomers were separated by fractional
crystallization by Richardson. This represented quite a feat at
the time19, and revealed ICI 46,474 to be more active as an
anti-implantation agent than its cis isomer ICI 47,699, which
was more estrogenic (Bedford and Richardson, 1966; Harper
and Walpole, 1966). In the meantime, Merrell had carried
out a spectroscopic analysis of their own drug clomiphene,
and disagreed with ICI’s interpretation of the spectroscopic
data, attributing the anti-estrogenic activity to the cis, not the
trans isomer. The controversy led to some confusion among
researchers, and eventually the matter was settled by X-ray
analysis, which confirmed ICI’s findings that the anti-estrogenic
activity did indeed reside in ICI 46,474, that is to say in the trans
isomer of the compound (Kilbourn et al., 1968).
So how did tamoxifen work? Before making a submission
to the CSD, which in the wake of the thalidomide disaster
had been set up to review all laboratory data on potential
drugs in advance of their introduction into human patients, a
basic understanding of their mechanism of action, as well as
knowledge about any toxic effects, had to be achieved (see Quirke,
2012a). Therefore, unsurprisingly perhaps since it was intended
for use in contraception, the first teratogenic test ever to be
performed by ICI was carried out with tamoxifen. At the very
low doses necessary to allow implantation of the fertilized ovum,
rat offspring developed a deformity called “kinky ribs.” However
no such effects could be seen in rabbits or in primates, and it was
later concluded that since ICI 46,474 restricts uterine growth, the
deformity was caused by mechanical contraction and therefore
could not considered a true teratogenic effect20.
Tamoxifen was most effective in preventing implantation in
rats when given on day 4 of the pregnancy, and virtually inactive
on day 5. This suggested that it acted by interfering with a crucial
event that had already occurred by the 5th day. It was suspected
18Walpole et al. “Reproduction” (AZ CPR 70/6B: Endocrinology, June 1964).
19John Patterson, personal communication, 20 April 2009.
20Richardson, “The history of Nolvadex.” It was later discovered that this effect
disappeared by the time of weaning (Jordan, 2006).
that ICI 46,474 prevented implantation by interfering with the
critical estrogen release on the uterus that occurs between 12
and 20–21 h on the 4th day21. However, it was unclear whether
the estrogen released at this time acted directly on the uterus
or whether its action was mediated by vasodilating amines
such as histamine. As there was evidence to support the latter
hypothesis, ICI 46,474 was thought to act either as a direct
estrogen antagonist, or by preventing the release of histamine, or
as an antagonist of the amine. To explore this hypothesis, whilst
carrying out further toxicity tests, experiments were devised in
additional animal species (as well as rats, in mice, rabbits, dogs,
monkeys, and sheep, for by then the compound was also being
considered for use in veterinary medicine)22. These experiments
revealed considerable species specificity, and by 1965 doubts
had arisen whether an “estrogen surge” was necessary for ovo-
implantation in humans, as it was in rats, and whether at
the dosage required to oppose estrogen sufficiently to inhibit
implantation ICI 46,474 would cause menstrual irregularities,
therefore whether the compound would prove effective and be
acceptable as an oral contraceptive23. Although it was still hoped
that ICI 46.474 would provide a welcome alternative to the now
familiar method of using mixtures of orally active estrogens
and gestagens (also known as progestogens) to inhibit ovulation
while at the same time producing withdrawal bleeding to replace
spontaneous menstruation, a method which was considered
too costly and too complicated for use in underdeveloped
communities, it was felt that such doubts could only be “settled
in the clinic24.” However, first, the team needed to ascertain
whether or not ICI 46,474 would produce irreversible damage to
the ovaries or uterus, and for this studies in monkeys, particularly
pig-tail monkeys in which changes in the reproductive cycle were
found to most closely resemble those in man25, were deemed to
be the most helpful.
The First Collaborative Trials (1967–71)
While these further studies were being carried out, ICI began
planning a trial with Dr. Klopper at Aberdeen, for the induction
of ovulation in amenorrheic women rather than contraception26.
Indeed, by then, clomiphene had been found to stimulate
ovulation and prolong luteal function in amenorrheic women,
and in 1967 was approved for the treatment of infertility in the
US27. Moreover, obtaining approval to evaluate ICI 46,474 in
oral contraception was problematic, not only because it involved
long-term administration, but because of persisting fears among
British gynecologists that it might lead to fetal malformation.
In their eyes, unlike the conventional pill which contained
21Walpole et al. “Reproduction” (AZ CPR 70/6B: Endocrinology June 1964).
22After it had been found to be estrogenic in sheep, in 1970 the compound was
even considered as a fattening agent for livestock. Walpole et al. (AZ CPR 101/16B
Endocrinology and Fertility 20 Feb. 1970).
23AZ CPR 101/1B Endocrinology and Fertility January 1965.
24Ibid.
25Walpole et al. (AZ CPR 101/20b Endocrinology and Fertility 28 June 1971).
These changes were measured by radio-immunoassay (plasma estradiol) as well
as protein binding (progesterone) once appropriate tests had been developed.
26AZ CPR 101/7B Endocrinology and Fertility, January 1967.
27Its introduction is said to have begun the era of assisted reproductive technology.
See Dickley and Holtkamp (1996).
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familiar ingredients such as estrogens and progestins that had
traditionally been given to pregnant women without harm to
the fetus, evidence of a lack of teratogenic effect in animal
experiments with an unknown compound like ICI 46,474 did
not constitute an adequate safeguard. Therefore, they believed
that the first women to receive ICI 46,474 as a contraceptive
must be offered an abortion, but under the terms of the 1967
Abortion Act this could only be offered to a very limited number
of women28. Two solutions to this conundrum were envisaged:
(1) to arrange a consortium of gynecologists to contribute such
patients to a central unit in the hope of collecting a reasonable
number fairly quickly; (2) to go abroad to a country, such as
Hungary, where abortion was accepted as a means of population
control. Meanwhile, therapeutic studies would be conducted to
provide the sort of doses to be used in contraceptive trials,
and approval to carry these out was obtained from the CSM in
1969. These studies included ICI 46,474 (now also referred to by
its brand name Nolvadex) for the treatment of anovulation or
menorrhagia associated with high levels of endogenous estrogen
(to be carried out at Aberdeen, Manchester and the Women’s
Hospital in Chelsea), and of breast carcinoma in 30 menopausal
and post-menopausal women (at the Christie Hospital in
Manchester).
The preliminary reports received from Dr. Klopper in
Aberdeen and Drs. Murray and Osmond-Clarke in London
helped to cast further light on the drug’s mechanism of action,
showing that that tamoxifen was capable of inducing ovulation at
higher dose levels, while at lower doses it tended to have an anti-
estrogenic effect29. As to the Christie breast cancer trial, although
two of the women complained about hot flushes (which was taken
as evidence of its anti-estrogen effect), no toxicity was observed
and the drug appeared to be well tolerated, even at the highest
dose of 10mg by mouth.
In her unpublished history of tamoxifen, Dora Richardson
wrote of the team’s excitement as the first trial results arrived. She
described the news of the birth of a child to a woman who had
been infertile for 12 years and had failed to respond to treatment
with clomiphene as a “boost to morale30.” She also described
how the team were encouraged by the results of the breast cancer
trial, even though these results were not received with universal
enthusiasm at ICI: Walpole and his colleagues were told that
they were supposed to be looking for a contraceptive pill, not
an anti-cancer agent! At a Development meeting on 28th August
1970, sales estimates and quantities of bulk drug were set at 2 kg
for initial stocks. Richardson concluded from these figures that
the Development Department obviously envisaged treating only
“dead people,” an indication of the hopelessness of the condition
as it was viewed at that time (as well as lack of faith or ignorance
on the part of the Development team)31. However, fortunately,
on the basis of the positive clinical results, the CSM granted
28It was thought that British gynecologists would be unlikely to come across more
than one woman a year to whom abortion could be offered under the new law.
Walpole et al. (AZ CPR 101/19B Endocrinology and Fertility, 19 Feb. 1971).
29Walpole et al. (AZ CPR 101/17B Endocrinology and Fertility 25 June 1970).
30Richardson, “The History of Nolvadex.”
31Ibid.
the company permission to prolong the trials as well as extend
them to other centers. By the end of 1970, 60 patients had been
admitted to the Christie breast cancer trial, and of the 40 women
who had been on the trial for more than 10 weeks, all had
shownmeasurable andmarked tumor regression. Although these
results were comparable to those achieved with the established
synthetic hormone diethylstilboestrol, the clinicians carrying out
the trial, Drs. Todd and Cole, reported how impressed they
were with the absence of toxicity and the low incidence as
well as trivial nature of any side-effects (Cole et al., 1971),
especially compared with other agents used in cancer at the
time, which were often either toxic, or—in the case of breast
cancer—tended to have androgenic effects, and in some instances
were so intolerable that patients had been withdrawn from
treatment32.
In return, the trials provided clinical material for laboratory
studies of tamoxifen. By then, the estrogen receptor had
been isolated and identified by Gorski (Gorski et al., 1968),
and Walpole and his team developed a receptor protein-
binding assay method33. However, in a clinical setting, it
was felt that a radio-immunoassay was more specific for
measuring blood-estradiol levels in patients given tamoxifen34.
The receptor-protein binding assay was therefore mainly used
for experiments in laboratory animals, and showed tamoxifen
to be a competitive inhibitor of estradiol binding to the uterine
receptor protein in rabbits and in mice. Receptors sensitive
to anti-estrogen were also found in various parts of rats’
brains, including the hypothalamus and the pituitary. The
results of the receptor-protein binding experiments in both
these test systems suggested that, like other anti-estrogens, the
action of tamoxifen was due to a high association constant
but low effectiveness of the complex it formed with estrogen
receptors (i.e., it was a partial agonist, with high affinity but
low intrinsic activity)35. This was a pharmacological action
with which ICI researchers had become familiar in their work
on the beta-blockers (Quirke, 2006). It helped to cast further
light on the physiological processes at a molecular level36,
and made tamoxifen a particularly useful research tool for
investigations of hormone-dependent tumors (Jordan et al.,
1972).
Rendered confident by the clinical and laboratory studies
carried out so far, Walpole’s team began planning trials in
contraception, and the Nolvadex Development Programme was
drawn up37. This would play an important part in the drug’s
transformation from quasi-orphan to blockbuster drug (Quirke,
2012b).
32Walpole et al. (AZ CPR 101/18B Endocrinology and Fertility, 28 Oct. 1970).
Norethisterone was a drug with such an androgenic effects. See Richardson, “The
history of Nolvadex.”
33Walpole et al. (AZ CPR 101/17B Endocrinology and Fertility 25 June 1970).
34Walpole et al. (AZ CPR 101/19B Endocrinology and Fertility 19 Feb. 1971).
35Tamoxifen is now classed as a selective estrogen receptor modulator (SERM),
meaning that it activates estrogen receptors in some tissues, while blocking them
in others.
36Walpole et al. (AZCPR 101/18B Endocrinology and Fertility 28Oct. 1970); idem,
(AZ CPR 101/19B Endocrinology and Fertility 19 Feb. 1971).
37AZ PH 19597 B: Nolvadex Development Programme, June 1971.
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The Nolvadex Development Programme
(1971)
The “Development Programme” was an organizational
innovation which standardized and codified the R&D process
at ICI. It marked the transition from the “Proving Trial” to the
“Development Trial Stage38,” thus helping to bring together the
“R” and the “D” in R&D39. ICI’s first Development Programme
had been written up in 1964 for the beta-blocker propranolol
(Inderal)40. It followed a series of quarterly development
reports41, and coincided with the hitherto separate Research
and Development Departments coming together under the
responsibility of a single Director, the Technical Director, as
well as with the creation of the CSD in 1963. It therefore was a
response to both internal and external factors and stimuli.
The Nolvadex Development Programme, which came 7 years
after the Inderal Development Programme, included 16 rubrics,
describing the work done up to June 1971 (the date of the start
of the Programme), making an assessment of the drug’s potential
market, and plans for future work:
1. Clinical trials




6. Process development and manufacturing of bulk drug
7. Manufacture and packing of tablets









Three important considerations were taken into account when
planning future work. First and foremost were tamoxifen’s
possible clinical uses, based on the results of trials received
to date. These included: treatment of estrogen-dependent
mammary carcinoma; induction of ovulation on women
suffering from infertility due to failure to ovulate; menstrual
disorders associated with abnormal levels of endogenous
estrogen; oral contraceptive (a) for women, (b) for men;
treatment for oligospermia; test for pituitary function; others.
Secondly, the drug’s position in North America was under
question, following Ayerst’s rejection of ICI’s offer of Nolvadex
for the American market, and the FDA’s likely negative attitude
toward its use in breast cancer. This attitude may have been due
to a 1971 report in JAMA which had suggested that there was a
38“Minutes of a meeting of the ICI 46,474 Development Team, Development
Department, held on 28th August 1970” (Appendix 4 of Richardson, “The history
of Nolvadex”).
39AZ PH 19597 B: Nolvadex Development Programme, June 1971.
40AZ PH15355B: Inderal Development Programme, 15 June 1964.
41AZ CPR 68B: Research and Development Quarterly Reports (1962-1964).
TABLE 1 | UK major branded products.
Annual sales
(NHS level)
Cost of 1 week’s
treatment
Provera 100 (Progestogen, Upjohn) £50,000 £3.15







SH420 (Progestogen, Schering) £27,000 £0.70
Source: AZ PH 19597 B: Nolvadex Development Programme (June 1971).
link between diethylstilbestrol and a rare form of vaginal cancer,
and was promptly followed by an FDA bulletin warning against
the use of DES (FDA, 1971). Thirdly, the commercial situation,
shown in Table 1, indicated that a number of therapeutic
treatments of hormone-dependent breast cancers were already in
existence, each of which commanded almost equal shares of the
market.
Despite such competition from rival firms in America
and Europe, tamoxifen had two advantages on which its
market position would ultimately depend in relation to breast
cancer: (1) its unique mode of action in being an estrogen-
antagonist without androgenic properties, and since at the
time it was the only product of its type its use should
be larger; (2) it possessed very low incidence of side-effects
compared with other forms of treatment. Another important
consideration was that of past R&D costs (shown in Table 2),
which had a bearing on budgeting and planning for future
expenditure.
The gaps in particular columns and rows in Table 2
exemplify the non-linear nature of pharmaceutical R&D, with
bottle necks and feedback loops when advances in one area
are held up by, and then develop in response to those in
another. They also illustrate the pivotal part played by drug
regulation in shaping the research and development activities
of pharmaceutical firms. The trials that followed the CSM’s
approval for Nolvadex in 1969 not only led to an increase
in existing expenditure in areas such as biochemistry, but
to new expenditure in areas such as formulation (shown in
bold).
As well as further trials in anovulatory infertility (in
Abderdeen, Oxford, London, and Dublin), and in breast cancer
(Manchester, Glasgow, and London), the Nolvadex Development
Programme included plans for trials in contraception. “In view
of the reluctance of British gynecologists” to become involved in
such trials, in 1971 ICI contacted Professor Egon R. Diczfalusy,
co-founder and Director of the WHO Research and Training
Centre on Human Reproduction at the Karolinska Institute in
Stockholm42, where he had already carried out collaborative
42Ian Askew, “Obituary: HPR co-founder, Egon R. Diczfalusy, 1920–2016,”
http://www.who.int/reproductivehealth/obituary-e-diczfalusy/en/ (accessed
02.06.17).
Frontiers in Pharmacology | www.frontiersin.org 8 September 2017 | Volume 8 | Article 620
Quirke Tamoxifen: A Case Study in Pharmaceutical Innovation
TABLE 2 | Nolvadex R&D costs (£’000).
1964 1965 1966 1967 1968 1969 1970 1971 Est 1972
Biology 6.7 1.7
Toxicology 9.6 9.5 10.0 2.2 1.7 1.1
Biochemistry 1.8 1.7 2.7 2.4 7.2 8.3 8.0 2.0
Analytical 1.8 0.2 0.9 0.4 0.2 1.5 5.0 3.0
Formulation 0.4 4.8 5.0
Process
development
1.9 0.1 5.0 14.7*
Medical 0.5 0.7 2.8 3.5 5.6 8.0
Development 0.5 0.4 0.5 1.0 1.7 2.0
Totals 21.8 12.9 12.9 4.2 5.6 10.7 19.7 40.9 20.0
*Including cost of bulk drug.
Source: AZ PH 19597B: Nolvadex Development programme (June 1971).
projects involving healthy human volunteers using estrogens and
other compounds43.
The Swedish trials led to the finding that, contrary to what
might be expected from the laboratory studies in rats, tamoxifen
stimulated rather than suppressed ovulation, and therefore would
not work as a contraceptive pill in women. The market for a
fertility drug was small, as seemed the market for an anti-cancer
drug, partly due to the poor prognosis associated with the disease.
Despite growing clinical evidence of the usefulness of tamoxifen
in breast cancer, the very low sales estimates produced by the
Marketing Department suggested that it was never going to cover
the R&D costs and bring an appropriate return to the company.
ICI’s Main Board therefore made the decision to close down
the Programme, but tamoxifen’s champion, Walpole, threatened
to resign. On this announcement, despondency spread through
the entire research department. Moreover, when informed of
the company’s decision, one clinician said that, in view of the
encouraging trial results, ICI could not morally withdraw the
drug44. By then, the breast cancer trials had led to a number of
publications, which sparked world-wide interest in tamoxifen45.
Under such pressure, the company reversed its decision, Walpole
remained, and the project was saved. In February 1973 ICI
applied for a product license, which was granted a few months
later, and in October of that year Nolvadex was launched in the
UK for both anovulatory infertility and the palliative treatment of
breast cancer. Although there continued to be crossovers between
the two projects, the rest of this paper will focus on breast cancer.
It will show how tamoxifen was transformed from a research
object and palliative therapy for advanced breast cancer, into
a diagnostic and predictive tool, an adjuvant chemo-endocrine
treatment first in post-menopausal, then also in pre-menopausal
women with early breast cancer, and eventually into the first
chemopreventative for cancer.
43Walpole et al. (AZ CPR 101/20B, 28 June 1971). On the WHO Research Centre
see: http://ki.se/en/kbh/who-center-for-human-reproduction (accessed 02.06.17).
See also Oudshoorn (1998).
44Richardson, “The History of Nolvadex”; see also Jordan (2003).
45Walpole et al. (AZ CPR 101/26B Fertility, 22 June 1973).
Tamoxifen, from Palliative Care to Adjuvant
Therapy (1973–75)
Among the large number of clinical trials now being carried
out with tamoxifen, Dr. Einhorn’s studies at the Karolinska
Institute in Stockholm had included a measurement of the
rate of DNA synthesis in breast tumors and the effect this
had on treatment. As a result, his group had been able to
anticipate clinical response to, or relapse after, treatment with
tamoxifen. From these observations, Walpole concluded that
tamoxifen could be employed in pre-menopausal women with
breast cancer for a short period as a tool to predict the usefulness
of drastic treatments such as ophorectomy in these women. At
the same time, he began making plans for a trial with Dr. J.
C. Heuson of the European Breast Cancer Group, who was
anxious to compare tamoxifen with Nafoxidine (an Upjohn
compound which like tamoxifen could bind to the estrogen
receptor, but unlike tamoxifen had several toxic side effects).
The trial would include estrogen receptor determinations on
biopsies taken from each patient to determine whether there was
a correlation between clinical response to the compound and the
presence of estrogen receptors in the tumor tissue46. By then, the
clinical trials in fertility and contraception had also shown that
in some instances tamoxifen led to the suppression of lactation.
Walpole felt that this action would be of interest in the context of
breast cancers which may be associated with high blood prolactin
levels, and indeed at Westminster Hospital two patients who had
responded well to tamoxifen had tumors which were thought to
be prolactin-dependent47. Taken together, these observations on
the measurement of DNA synthesis before and after treatment, of
the content of estrogen receptors in breast tumors, and of blood
prolactin levels led to the hope that it would be possible to predict
the type of patient likely to respond to treatment with tamoxifen,
i.e., to develop what is now referred to a “stratified therapy”
(i.e., a re-branding of what was formerly known as “personalized
medicine”; Smith, 2012).
However for this to happen, better screens had to be devised,
first in animals and then in humans. In her unpublished history of
tamoxifen, Dora Richardson commented that no laboratory tests
for anti-tumor activity had been carried out with tamoxifen until
after its activity in patients had been confirmed. The laboratory
model adopted by Walpole’s team to test for tumor inhibition
was the DMBA (dimethyl benzanthracene) induced tumor in
rats (also known as the Huggins tumor). The next step was to
design a simplified method of receptor analysis, which could be
applied routinely on a large scale in this model, before being
applied in humans48. Walpole’s team developed such a method
in collaboration with Craig Jordan (from the Department of
Pharmacology at Leeds University, who at the time was on
leave of absence at the Worcester Foundation for Experimental
Biology, USA, and whose work would later be sponsored by
ICI; (Jordan, 2006), pp. 40–41). If it proved effective, i.e., if
it demonstrated that tamoxifen could bind to the estrogen
46Ibid.
47The presence of prolactin in human blood had been confirmed by Henry Friesen
et al. (1970).
48Walpole et al. (AZ CPR 101/27B Fertility 24 Oct. 1973).
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receptor in human breast tumors, it was hoped that this method
would make it possible to screen patients for the presence of
specific estrogen receptor in biopsy specimens of their tumors
and to pre-select for treatment with Nolvadex those in whom
such receptors had been found. However, alongside these highly
scientific methods, clinicians continued to use observations such
as “hot flushes” as indications that the treatment was working
and remission was likely to occur49. Walpole therefore proposed
that physiological indicators might also be used to ensure that
individual patients were not being “under-treated” and could
be given the maximum effective dose to produce an improved
response50.
In his report of February 1974, Walpole wrote: “By good
fortune, Nolvadex was launched at a time of increased interest
in the assessment of the endocrine status in breast cancer51.”
Tamoxifen was shown to be highly effective in binding to the
estrogen receptor and, before long, researchers in Europe and
the US were therefore using tamoxifen as a tool to “predict
the response of breast tumors to hormone therapy52.” However,
this new use for tamoxifen brought out the fact that not all
patients whose tumors had demonstrable estrogen receptor levels
responded well to endocrine therapy. Although this paradox
might be due to the fact that the receptor assays used were not
of consistent standard, it suggested that a number of biochemical
events were a pre-requisite for complete endocrine regulation,
and that other lesions occurred in patients for whom endocrine
therapy failed, thereby casting further light upon the complex
processes involved in malignant disease.
Nolvadex was also launched at a time when the value of
chemotherapy in cancer was being established with novel drugs
tested first alone, then combined, in collaborative multi-center
trials (see Keating and Cambrosio, 2007; also Quirke, 2014, pp.
670–671).With drug resistance becoming a growing concern, not
only in bacteria, but also in cancer cells, combination therapy
was being developed and its modalities refined. Hence, in June
1974, Walpole began planning a trial in which two different
treatment modalities, supposedly devoid of cross-resistance,
would be used, and he proposed to alternate their administration
on a 4-week basis53. The rationale for this trial was that, unlike
conventional sequential treatments, each alternating treatment
would be started before rather than after the effect of the previous
one was exhausted, thus resulting in a cumulative effect. Two
added benefits of such an approach were that (1) drugs with
high levels of toxicity, such as adriamycin and vincristin, could
be given for much longer, and (2) at precise moments in the
treatment cycle, the patient’s bone marrow and immune system
would have a chance to recover. This approach was tried by
49Walpole (AZ CPR 101/28B Fertility 26 Feb. 1974).
50Walpole (AZ CPR 101/28B Fertility 16 June 1974).
51This interest was stimulated by observations such as Jense’s (Jense et al., 1971),
who showed that patients with tumors containing high affinity estrogen receptors
were more likely to have a remission following adrenalectomy than those without
such receptors (with remissions in 10/13 patients with positive tumors, but in only
1/26 patients without).
52Walpole et al. (AZ CPR 101/32B Fertility 27 June 1975). One of these researchers
was W. L. McGuire in the USA. See McGuire et al. (1975).
53Walpole (AZ CPR 101/28B Fertility 14 June 1974).
Dr. Heuson under the aegis of the European Organization for
Research and Treatment of Cancer (EORTC, which had been
created in 1962), alongside another trial in pre-menopausal
women54.
Such plans and discussions, which were based on a growing
number of publications and symposia presenting evidence not
only of symptom relief, but also of remissions and survival
from breast cancer55, indicate that, both as a research tool
and a therapeutic agent, tamoxifen was shifting from palliative
care into the realm of chemotherapy, transforming it in the
process. What follows will concentrate on the years 1975–1980,
after which ICI’s research reports on tamoxifen and related
topics ended. During that period Walpole was mainly involved
in the Nolvadex Development Programme until his sudden
death in 1977. Although his involvement ensured continuity
between the research and development phases, Walpole’s gradual
disengagement from the research, which can be detected in
the reports, meant that the project lacked clear purpose and
direction. Months were lost to pressures of competing work
inside the company, and aspects of the research were outsourced
to external laboratories (Jordan, 2006, Chapter 3). Nevertheless,
in that time, the foundations were laid for the next phase
in tamoxifen’s trajectory, from adjuvant therapy to the first
chemopreventative remedy for cancer.
1975–1980: The Final Years of ICI’s
Tamoxifen Project
Clinical trials carried out in Britain by Ward (Birmingham) and
Brewin (Glasgow) and beyond (in Germany) showed that the
response to tamoxifen in patients who experienced a recurrence
of their breast tumor after primary surgery and/or radiotherapy
tended to increase with age56. These findings prompted the
question of what the mechanism for this action might be, since
tamoxifen was an “anti-estrogen.” Could it be that tamoxifen
exerted an estrogenic action (albeit a weak one) by way of
its metabolites?57 The study was taken up at ICI by Barry
Furr58 and B. Valaccia, and a programme of synthesis and
tests of analogs of tamoxifen metabolites in a number of
different screens, not only estrogen, but also progesterone and
androgen receptor screens, was initiated to find out whether
tamoxifen could bind with them, and therefore be useful in
other cancers. Later prostaglandin synthetase (PGS) inhibitor
screens were also developed by the team. These showed that
tamoxifen was an effective inhibitor of human breast tumor
PGS in addition to arresting tumor growth, thus offering an
explanation for the clinical observation that patients taking
Nolvadex for advanced breast cancer often experienced relief
from bone pain, and strengthening the rationale for its use
54Walpole (AZ CPR 101/32B Fertility 27 June 1975). For more on the history
of EORTC see: http://www.eortc.org/history/ (accessed 05.06.17). Its journal, the
European Journal of Cancer, was launched in 1965.
55Bonadonna et al. “Cytotoxic chemotherapy for mammary cancer,” Symposium,
Padova, 8 Apr. 1974, quoted in Walpole (AZ CPR 101/28B Fertility 16 June 1974).
56Walpole (AZ CPR 101/32B Fertility 27 June 1975).
57Gregory (AZ CPR 101/34B Fertility 17 Feb. 1976).
58“Professor Barry Furr” Obituary: https://alumni.reading.ac.uk/our-alumni/dr-
barry-furr (accessed 10.06.17).
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in adjuvant chemotherapy further still. Hence, it was hoped
as a result of this programme that a follow-up compound for
Nolvadex might be found—the target being an anti-estrogen
of similar potency to Nolvadex with one or more of the
following properties in addition: lower agonist activity, shorter
half-life, greater inhibitory activity against PGS, anti-androgenic
activity59.
This new research strand, which would lead ICI to its second
major breakthrough in cancer therapy: ICI 118,630 (goserelin,
Zoladex), was stimulated by the discovery by Schering Plough of
the first non-steroidal anti-androgen Flutamide for the treatment
of prostate cancer. As they had done earlier with Merrell’s
drug, ICI therefore mobilized their synthetic capabilities and
the scientific expertise acquired with tamoxifen to search for a
non-steroidal anti-progestin (which unlike anti-androgens would
have the advantage of having neither anti-anabolic activity nor
any effects on “normal sexual behavior”)60. Another approach
consisted in looking for a novel, potent analog of the luteinizing
hormone-releasing hormone (LHRH), also referred to as the
gonadotrophin-releasing hormone (GnRH), although this was
initially expected to be used mainly in animal breeding61. As
well as testing the compounds in the company’s by now well
established receptor-binding assays, once again the team needed
to develop new in vivo screens, and “in view of the previous
experience with Nolvadex, that is anti-estrogenic in the rat and
estrogenic in mice,” tests would have to be carried out in more
than one species. Because the chick comb was known to be
androgen sensitive and chicks were cheap, it was chosen as one
of the animal models in which to test active compounds and
compare them to Flutamide.
Meanwhile, a special organization had been created for the
purpose large-scale clinical studies of tamoxifen as an adjuvant
treatment for cancer: the Nolvadex Adjuvant Trial Organisation
(NATO). Until then, adjuvant therapy had consisted either
in chemotherapy using mainly cytotoxic drugs, or in major
endocrine ablation after curative surgery. Clinical trials of
tamoxifen in adjuvant therapy therefore began in 1976, some
progressing ahead of schedule, and their favorable results, which
showed that Nolvadex was effective in both pre- and post-
menopausal women regardless of their receptor status, were
frequently discussed at symposia and in the medical press from
1977 onwards62. Not only did these results change the modalities
of adjuvant therapy for breast cancer whilst helping to establish
tamoxifen in the treatment of the early stages of the disease
(NATO, 1983, 1988), but in the context of these adjuvant trials
evidence also emerged of the drug’s potential to prevent the
recurrence of breast cancer in women at high risk (i.e., who had
already had cancer in one breast). This potential was explored
in a trial carried out in Denmark, with the aim of establishing the
value of tamoxifen as a “prophylactic” in breast cancer (Andersen
et al., 1981; Mouridsen et al., 1988). Patients were selected
who had had a mastectomy with or without radiation and in
59Crossley (AZ CPR 101/37B Fertility 27 Jan. 1977).
60Ibid.
61Ibid.
62Richardson, “The history of Nolvadex.”
whom there was no evidence of metastases, for it was known
that 55–60% of them would develop local recurrence of the
disease or metastases within 5 years. They were then randomly
allocated either to Nolvadex, stilboestrol, or a placebo63. The
trial eventually showed that although 10% of the women treated
with placebo developed a recurrence of their breast cancer,
none of those treated with tamoxifen had experienced such a
recurrence64. Such results would later help to justify the initiation
of breast cancer prevention trials, for instance the Breast Cancer
Prevention Trial NSABP-P1 (BCPT), with the aim of establishing
whether 5 years of tamoxifen would reduce the incidence of
invasive breast cancer in women identified as being at high risk
of the disease, and yet healthy (Fosket, 2010; Löwy, 2012; also
Fosket, 2004).
Almost as soon as it had moved into the realm of cancer
chemotherapy, tamoxifen therefore hinted at the theoretical and
practical possibilities of chemoprevention in cancer. Further
trials would turn tamoxifen into the first preventative for
any cancer, helping to establish the broader principles of
chemoprevention, while extending the market for tamoxifen
and similar drugs further still (Early Breast Cancer Trialists
Collaborative Group, 1992, 1998)65.
Tamoxifen, from the Clinic into the Medical
Marketplace
Thanks to tamoxifen, ICI were able to tap into the vast cancer
research network connected in Europe through the EORTC,
and across the Atlantic through the National Cancer Institute
(NCI). The interest tamoxifen generated among scientists and
clinicians, rather than the promotional activities of the company,
which Dora Richardson argued remained very limited, greatly
enhanced its position in the medical marketplace. In a personal
communication to Walpole, Dr. Scott Lippman of the NCI had
described his method for testing tamoxifen in human breast
cancer cell lines which were dependent on estrogens for their
long-term growth in tissue culture66. In these cells, tamoxifen
showed itself to be strongly inhibitory of both DNA and protein
synthesis. Lippman had turned this method into a “kit” for
measuring receptors, and spurred by their American subsidiary
(ICI-USA), ICI did not waste time in starting work on their
own quantitative assay “kit to be marketed as an adjunct to
Nolvadex.” Such a kit would not only make money for itself, but
by helping to justify the use of tamoxifen, would further enhance
the market position for the drug, particularly in the USA67. By
then, the company had submitted an Investigational New Drug
(IND) application to the Food and Drug Administration (FDA).
It was followed in 1976 by a New Drug Application (NDA)
to the FDA’s Oncological Drugs Advisory Committee, in which
John Patterson, a member of ICI’s Clinical Research Department
(formerly of the Medical Department), made a detailed and
63Walpole (AZ CPR 101/32B Fertility 27 June 1975).
64Richardson “The history of Nolvadex”.
65NB: the FDA approved tamoxifen for the reduction of breast cancer risk in 1998.
66Walpole, (AZ CPR 101/32B Fertility 27 June 1975).
67Crossley (AZ CPR 101/33B Fertility 2 Oct. 1975). Such kits, which would now
be referred to as “companion diagnostic tests,” remain a mainstay of breast cancer
therapy today.
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convincing case for Nolvadex in breast cancer68. By 1984, the
NCI were describing tamoxifen as the adjuvant chemotherapy of
choice for breast cancer (Consensus Conference, 1985). Although
ICI’s application for a US patent for tamoxifen had originally
been rejected on the basis that the US Patent Office did not
recognize advances on existing inventions, and that Merrell’s
patent for clomiphene pre-dated that for tamoxifen, in 1985 the
American court of appeals finally granted ICI the patent rights for
tamoxifen in the USA, thereby starting the 17-year patent cover
there, paradoxically at a time when it was coming to an end in
other countries (Jordan, 2006, p. 40).
Tamoxifen’s entry into the American market contributed to
rising worldwide sales: although ICI’sMarketing Department had
only expected it to make £100,000 p.a. in 1970, by 1974 figures on
the home market alone amounted to £140,000, overtaking one
of ICI’s well established drugs Mysoline (for epilepsy). By 1976,
sales figures were equivalent to those for the anesthetic Fluothane,
the first drug to put ICI’s Pharmaceutical Division “in the black,”
and for over-the-counter drugs such as, the antiseptic Savlon. As
the expiry date for their tamoxifen patents was drawing near, in
1979 ICI obtained a 4-year extension for their UK patent, on the
basis of “the nature and merits of the invention in relation to the
public,” as well as “the profits made by the patentee69.” By 1980,
it was making £30 M for the firm70.
Nevertheless, even as late as September 1982, at the annual
portfolio review attended by the managers of the Biology
Department (Dr. J. D. Fitzgerald) and Chemistry (Dr. R.
Clarckson), the manager of the Marketing Department, who
also attended the meeting, commented that “there was no
market for cancer71.” ICI’s Marketing Department were not
alone in under-estimating the market for anti-cancer drugs:
if tamoxifen had not been “stolen” by American companies
while it remained unprotected by patents, it was partly because
they did not believe in its usefulness either (Jordan, 2006, p.
40). The fate of tamoxifen therefore rested on the qualities of
the drug itself, and the interest it generated not only among
researchers both inside and outside the company, but also among
patients and the wider public. As mentioned earlier in this paper,
Dora Richardson’s history of Nolvadex was—quite unusually
for such an internal publication—accompanied by letters from
patients who attributed their lives to tamoxifen. Appendix 6
entitled “What do the patients think” included a letter to ICI’s
Pharmaceutical Division, in which a grateful patient wrote:
“Thank you for a miracle.”
Tamoxifen benefited not only from being the first of a kind,
which helped to confer upon it the status of a “miracle drug,”
but once again from its origins as a contraceptive pill. As
the name indicates, it could be taken orally, and this mode
of administration meant that Nolvadex was suitable for home
treatment, and a large proportion of sales (75%) occurred
68Richardson, “The History of Nolvadex.”
69UK 1949 Patents Act, Section 23. http://www.legislation.gov.uk/ukpga/1949/87/
pdfs/ukpga_19490087_en.pdf (accessed 15.06.17). I thank Dr. Michael Jewess for
pointing out this section to me.
70Richardson, “The History of Nolvadex.”
71Dr. J.D. Fitzgerald, personal communication.
through retail pharmacies. This enabled local tinkering with
established protocols, as well as a degree of self-experimentation,
as testified by another letter, written by a cancer researcher (Dr.
June Marchant of the Regional Cancer Registry, West Midlands
Oncology Group), who had been diagnosed with breast cancer,
and having spent 20 years in cancer research was well versed in
themodalities of cancer therapy72. After discussing her ideas with
her clinician, whom she described as “understanding,” together
they worked out “an unconventional management programme.”
Because her thymus gland was within the radiation field of
her breast tumor she refused radiation therapy. Instead, she
decided to undergo therapy with a new cytotoxic drug that
was being tested locally in a clinical trial. She appeared to
make an uneventful recovery, but in 1972 a scan revealed
metastases in her brain. At this point, she therefore elected
local treatment with radiation of the head and adjuvant therapy
with tamoxifen. Knowing from her own research that prolactin
had been identified as a hormone with perhaps an even greater
significance than estrogen in themaintenance of breast tissue and
breast tumor growth, she started reading the relevant literature.
A number of inhibitory substances had been tried on a few
patients with breast cancer, and among them Levodopa appeared
to give beneficial results. Her clinician therefore agreed to give
her Levodopa as additional anti-hormonal therapy. Her drug
regimen was phased out in 1975, and at the time of writing her
letter, in 1976, the author felt “very well indeed, having had no
ablative operation, cytotoxic drugs or masculinizing hormones.”
From her own experience, she therefore concluded that “systemic
therapy, in addition to local therapy, had a vital role to plan in the
management of the disease,” and she wished to share this positive
experience with others.
Her conclusions went beyond ascertaining the value
of tamoxifen in adjuvant therapy—extrapolating from her
experience with the drug, she defended “systemic therapy” more
generally. Yet, after Dr. Stephen Carter, who had been responsible
for ICI’s cancer project on Cell Division and Growth73, left the
company, taking early retirement in 1979, he was not replaced,
and the project on cell growth was terminated. Thus, in 1980,
when tamoxifen was bringing in sizeable profits for the company
and Zoladex (for prostate cancer) was in the pipeline, ICI had no
longer a cancer research programme, a situation that lasted until
in 2006, when Alderley Park became the Global Lead Centre for
the company’s cancer research74.
DISCUSSION
If tamoxifen made it into the medical marketplace, it was
largely despite rather than because of the company’s marketing
72Dr. June Marchant, “Personal view” (27 November 1975), Appendix 6 of
Richardson, “The History of Nolvadex.”
73AZ CPR 110 (1965-77): Cell Division and Growth.
74On Alderley Park, see AstraZeneca, “Alderley Park, Cheshire,” http://
www.pharmaceutical-technology.com/projects/astrazeneca-alderley/ (accessed on
15.06.17). This has become Manchester’s new bioscience campus: https://mspl.co.
uk/campuses/alderley-park/ (accessed on 15.06.17), while AZ’s UK R&D center
has been relocated to Cambridge see: https://www.astrazeneca.com/our-science/
cambridge.html (accessed 15.06.17).
Frontiers in Pharmacology | www.frontiersin.org 12 September 2017 | Volume 8 | Article 620
Quirke Tamoxifen: A Case Study in Pharmaceutical Innovation
department. Thanks to having inside a drug champion prepared
to risk his career to save his project and a medical department
willing to run the gauntlet of the FDA to promote tamoxifen in
the USA, but also thanks to interest generated outside, among
scientists, clinicians, and patients who asked for or agreed to
take the drug, it was transformed from a failed contraceptive
pill into a successful breast cancer medicine. The patients’ letters
referred to in this essay provide us with a unique insight
into this transformation, but also into the public demand and
experimentation which escape the control of both the industry
and the professions, and are not normally included in discussions
of pharmaceutical innovation.
Focusing on the early history of tamoxifen has made it
possible to examine in some detail both the brakes and the
stimuli for pharmaceutical innovation. These come from inside
as well as outside industry, contrary to a rather narrow model
of pharmaceutical innovation, according to which companies,
motivated by a commercial more than a scientific agenda, push
drugs onto an unsuspecting public, often with the connivance
of the medical profession, but hopefully kept in check by the
actions of regulatory authorities (for example see: Crawford,
1988; Marsa, 1997; Law, 2006).
In the case of tamoxifen, pharmaceutical innovation was
predominantly science- and clinic-driven, rather than market-
driven (so a case of demand-pull rather than supply-push,
Walsh, 1994). It benefited from a number of coincidences:
its ability to bind to the newly-discovered estrogen receptor
helped to make it into a useful tool for investigating hormone-
dependent tumors, as well as a drug of choice for treating breast
cancer. It was developed at a time when palliative care was
becoming an important part of cancer treatment (Clark, 2007),
and when chemotherapy was successfully being applied to cancer
in collaborative trials. These placed ICI at the center of a global
network of cancer institutions and organizations, which helped
to maintain interest in their drug even as ICI was losing its
research focus on cancer. Hence the last phase in tamoxifen’s
transformation, into the first chemopreventative for cancer, owed
more to this global network than to ICI’s efforts at promoting
their drug. Finally, tamoxifen was developed at a time when
cancer patients were encouraged to demand better treatments, to
become more proactive in their own care, and engage with ideas
of risk.
In the beginning, when tamoxifen was being developed as
a contraceptive pill, cancer patients had to some extent been
used as “proxies” for normal, healthy human subjects, and their
voices were mostly heard trough the clinicians who reported on
their symptoms as indications of the drug’s activity and side-
effects. Nevertheless, the fact that their voices were included,
both indirectly in the reports and directly in Dora Richardson’s
history of Nolvadex, suggests that to the company these voices
did matter: they helped to shape the content of the research,
whilst justifying it, both morally and scientifically. Rather than
a “detour” in relation to contraception (Oudshoorn, 2002), the
study of tamoxifen in breast cancer was therefore carried out in
close parallel with its study in contraception (and subsequently
fertility). This is not surprising, given that ICI’s interest in
cancer pre-dated their interest in contraception by 20 years.
Nevertheless, the contraception project helped to determine
tamoxifen’s fate as a drug: from what it was (a synthetic anti-
estrogen, safe with a relatively low incidence of side-effects), to
how it could be taken (orally, and therefore suitable for home
treatment).
Thus, the drug and its fate were shaped by the industrial
setting from which it emerged. In return, tamoxifen transformed
the biomedical landscape in which it was deployed. As it moved
from contraception into cancer, tamoxifen expanded its market
at the same time as its clinical role, transforming cancer therapy
in the process. Not only did it cast fresh light on the function
of sex hormones and their role in malignant disease, but it
hinted at the possibility of personalized medicine, and helped to
lay the foundations of chemoprevention. Indeed, although the
concept of chemoprevention had already begun to take hold with
drugs to treat cardiovascular diseases (to lower cholesterol or
blood pressure, for instance), by becoming associated with and
tapping into the drive to catch cancer early by screening and,
even better, prevent it by introducing life-style and other changes,
the principles and practice of chemoprevention were further
strengthened by drugs like tamoxifen and their application to the
field of cancer.
In the context of cancer chemoprevention, the question of
its use in normal, healthy women arose once more, but it did
not go unchallenged. In her chapter on “Breast Cancer Risk
as Disease”, Jennifer Fosket has described the controversies
that surrounded the BCPT which took place in the USA in
the 1990s, highlighting the fact that the risks associated with
tamoxifen were often downplayed, and this despite letters from
ICI (which had spun off its pharmaceutical division to form
Zeneca) warning both doctors and women enrolled on the trials
that—by then—some women taking tamoxifen had developed
endometrial cancer (Fosket, 2010, p. 345). Although the BCPT
identified an increased risk of pulmonary embolism, deep-vein
thrombosis, as well as endometrial cancer in women who had
taken tamoxifen compared to the control group on placebos,
their findings were nonetheless favorable to tamoxifen: only 124
women had developed breast cancer in the tamoxifen group,
compared to 244 in the placebo group (Fisher et al., 1998). On
the other hand, the results of the Royal Marsden Study, carried
out in the UK at roughly the same time as the BCPT, were not so
clear-cut: they revealed no significant reduction in breast cancer
incidence in women at risk who took tamoxifen (Powles et al.,
1998). These different results were attributed to key differences
between the American and European trials, ranging from their
organization, to the numbers of women enrolled, the criteria
for their selection, and different conceptualizations of what
constituted “high risk75.” Such differences and controversies
surrounding the trials led the FDA to downgrade its approval
from “prevention” to “reduction of risk” (Fosket, 2010, p. 348).
In a sense then, tamoxifen had been the victim of its own
success. Originally intended for women with little chance of
75Foskett has suggested that Royal Marsden selected women based on their family
history, and this may have led to more women with the BRCA1 and 2 gene
mutations, for whom tamoxifen is a less effective preventative, being enrolled in
the trial (Fosket, 2010, n. 2 p. 352).
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survival, its ability to cause disease in women experiencing
long-term remissions thanks to tamoxifen led to a complex
assessment of risk, which had to be shared with women
undergoing treatment for breast cancer. Thus, in 1996, a guide
written for clinicians and patients on the subject of tamoxifen
stressed the importance of communicating the risks involved in
taking the drug, from minor side effects such as hot flushes, to
potentially serious ones including other cancers. Hence, what was
nevertheless a message of hope did not only relate to tamoxifen
itself, but also to the “new patient” which caring professionals,
breast cancer advocates, and the media had helped to create:
“prepared with background information about the disease”;
requiring “treatment options”; wanting “good communication
and information” and wanting “the truth” (Langer, 2006, p. 134).
Such patients did exist, as we saw in the case of June Marchant,
even though she may have been exceptional, and in many ways
drugs like tamoxifen had also helped to bring them about.
CONCLUDING REMARKS
The focus of this paper on the industrial context for the
development of tamoxifen highlights the importance of the early
phases in the history of pharmaceutical innovation, for this early
history shapes the form and content of drugs, has the potential
to define their use and ultimately determine their fate in the
medical marketplace, and this despite the many twists and turns
that characterize their trajectory from bench to bedside.
This particular focus also throws into sharp relief the
contribution made by applied research to the advancement of
scientific knowledge: in the case of tamoxifen, more specifically
to the understanding of basic physiological processes involved in
human reproduction and malignant disease. Such a contribution
is in part due to the fact that industry, perhaps more easily than
academia with its rigid disciplinary boundaries, enables a to-ing
and fro-ing between separate, yet contiguous research projects
and therapeutic areas (in this instance, between contraception,
fertility, and cancer). This to-ing and fro-ing between projects
illustrates once again the non-linear nature of pharmaceutical
innovation. Typified by blind alleys, fresh departures, feedback
loops between the laboratory and the clinic, as well as
serendipitous discoveries, the early history of tamoxifen brings
to the fore the role of human agency, the institutional memory
that is often associated with long-term investment in particular
areas of expertise, and is embodied in individual researchers like
Walpole.
Just as the industrial context is worthy of historical enquiry,
the early history of drugs such as, tamoxifen, which are at
once emblematic and idiosyncratic examples of pharmaceutical
innovation, may yield useful lessons for potential innovators, by
helping them to identify key moments when choices are made
and decisions taken, so that these may in time be revisited and
alternative paths may be explored. For innovators are at once the
makers and the products of history, even if history is often remote
from their concerns or absent from their writings. Unfortunately,
because of the growing difficulty of accessing pharmaceutical
archives, this rich vein of historical enquiry may fast be coming to
an end. The hope remains that, as an essential component of their
intellectual capital, such archives will continue to be available to
researchers both inside and outside companies.
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